ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc (ARCT)

7,30
-0,74
(-9,20%)
Fermé 06 Juin 10:00PM
7,30
0,005
(0,07%)
Après les heures de négociation: 1:32AM

Arcturus Therapeutics Holdings Inc (ARCT) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
7,30
( -9,20% )
Prix Achat
7,44
Prix Vente
7,80
Volume échangé
412 918
7,23 Fourchette du Jour 8,02
5,85 Plage de 52 semaines 24,17
Cap du marché
Clôture Veille
8,04
Ouverture
7,96
Dernière Transaction
1
@
7.57
Dernière heure de transaction
Volume financier
US$ 3 095 500
VWAP
7,4966
Volume moyen (3 m)
US$ 474 332
Actions en circulation
28 423 069
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-2,79
Bénéfice par action (BPA)
-2,84
Chiffre d'affairess (LTM)
54,71M
Bénéfice net (LTM)
-78,67M

À propos de Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also dev... Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
San Diego, United States
Fondé
2026
Arcturus Therapeutics Holdings Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker ARCT. Le dernier cours de clôture d'Arcturus Therapeutics était de US$8,04. Au cours de la dernière année, les actions de Arcturus Therapeutics ont été négociées dans une fourchette de prix de US$ 5,85 à US$ 24,17.

Arcturus Therapeutics compte actuellement 28 423 069 actions en circulation. La capitalisation boursière d'Arcturus Therapeutics est de US$207,49 million. Arcturus Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.79.

ARCT Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.59-7.477820025357.898.197.2954887537.81908982CS
4-0.92-11.19221411198.229.586.6654913857.78846095CS
120.253.546099290787.059.586.364523147.81116716CS
260.466.725146198836.849.586.0154835677.49819816CS
52-4.93-40.310711365512.2324.175.8569798311.6728294CS
156-19.36-72.618154538626.66455.8552829018.77699493CS
260-23.65-76.413570274630.9564.97355.8555095823.03537718CS

ARCT - Frequently Asked Questions (FAQ)

What is the current Arcturus Therapeutics Holdings Inc share price?
The current share price of Arcturus Therapeutics Holdings Inc is US$ 7,30
How many Arcturus Therapeutics Holdings Inc shares are in issue?
Arcturus Therapeutics Holdings Inc has 28 423 069 shares in issue
What is the market cap of Arcturus Therapeutics Holdings Inc?
The market capitalisation of Arcturus Therapeutics Holdings Inc is USD 207,49M
What is the 1 year trading range for Arcturus Therapeutics Holdings Inc share price?
Arcturus Therapeutics Holdings Inc has traded in the range of US$ 5,85 to US$ 24,17 during the past year
What is the PE ratio of Arcturus Therapeutics Holdings Inc?
The price to earnings ratio of Arcturus Therapeutics Holdings Inc is -2,79
What is the cash to sales ratio of Arcturus Therapeutics Holdings Inc?
The cash to sales ratio of Arcturus Therapeutics Holdings Inc is 4,11
What is the registered address of Arcturus Therapeutics Holdings Inc?
The registered address for Arcturus Therapeutics Holdings Inc is 10285 Science Center Drive, San Diego, California, 92121
What is the Arcturus Therapeutics Holdings Inc website address?
The website address for Arcturus Therapeutics Holdings Inc is arcturusrx.com
Which industry sector does Arcturus Therapeutics Holdings Inc operate in?
Arcturus Therapeutics Holdings Inc operates in the Biotechnology & Life Sciences sector

ARCT Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock